Multiple Sclerosis Clinical Trials in New York

Showing 381-385 of 385 trials

Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer

NCT00036517

The triple combination chemotherapy of irinotecan, 5-fluorouracil and leucovorin (CPT-11/5-FU/LV or Saltz regimen) is the treatment of choice for patients with advanced colorectal cancer. Severe diarrhea, unfortunately, is a side effect of such treatment. Preclinical studies have indicated that the botanical drug PHY906 can reduce such diarrhea without compromising the effectiveness of the chemotherapy. The primary purpose of this clinical study is to evaluate the safety, tolerability and minimum effective dose of PHY906 when administered in conjunction with the Saltz regimen.

Colorectal NeoplasmsDiarrhea

PhytoCeutica30 participantsStarted Feb 2002

West Haven, Connecticut, United States • New York, New York, United States • Greenville, South Carolina, United States

COMPLETEDPHASE2< 1 mile

D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

NCT00047476

To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.

FatigueNeoplasms

Celgene Corporation160 participantsStarted Jun 2002

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Flagstaff, Arizona, United States +18 more locations

Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer

D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

Multiple Sclerosis Trials in Other Cities

Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer

Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.

Study of NS-9 in Patients With Liver Metastases

Other Conditions in New York